ClinicalTrials.gg
RecruitingNCT07226661Updated Nov 16, 2026

Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder

A Phase 2 interventional study of SPN-821 2400 mg and Placebo in Major Depressive Disorder (MDD), sponsored by Supernus Pharmaceuticals, Inc.. Recruiting at 40 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Supernus Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.
Updated Nov 16, 2026Study contact changed40 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
230
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 1,500 studies in Depressive Disorder, Major with a site in United States — 215 open to participants now, 257 under way, 26 of them phase 3. Depressive Disorder, Major · United States.

Planned enrollment
314th of 1,323
230 · median 70
Started
2026
with 81 others
Phase 2
271 of 1,500
45 open now
Primary completion
2026-12
later than 43 of 256 live
Registered
1,430th of 1,500
by date

Among the 1,500 studies in Depressive Disorder, Major with a site in United States, this one is the 314th largest by planned enrollment of the 1,323 interventional ones that give a count, is one of 82 that started in 2026, is one of 271 in phase 2, reaches primary completion later than 43 of the 256 other live ones, and was the 1,430th registered.

Depressive Disorder, Major

3,050 studies on the registry are indexed under Depressive Disorder, Major; 594 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

215 of the 1,500 studies in Depressive Disorder, Major with a site in United States are open now. Recruiting first, the newest first:

210 more — sign in →

All 215 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 417 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 297 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,500 studies in Depressive Disorder, Major with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of SPN-821 in adults with major depressive disorder

Read the detailed description

This is a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of SPN-821 administered twice a week as adjunctive therapy to an approved antidepressant therapy in adult participants with MDD. The study includes a 2-week Screening Period, a 4-week Double blind Treatment Period, and a Safety Follow-up phone call one week after the completion of the Treatment Period.

03

Conditions studied

  • Major Depressive Disorder (MDD)
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Current diagnosis of MDD according to the for either single or recurrent MDE without psychotic features confirmed by the MINI
  • Duration of current MDE of at least 8 weeks
  • MADRS total score of ≥ 24 at the Screening Visit and Day 1 Visit
  • CGI-S score of ≥ 4 (moderately ill or worse) at the Screening Visit and Day 1 Visit
  • Stable, therapeutic dose of one of the following protocol-approved ADTs as a monotherapy for ≥ 8 weeks before the Screening Visit and ≥ 10 weeks at the Day 1 Visit. Additionally, inadequate response to the current ADT (less than 50% improvement in depressive symptoms) as confirmed by the ATRQ Investigator administered.

Exclusion criteria

Exclusion Criteria:

  • MADRS total score change of ≥ 25% from the Screening Visit to Day 1 Visit
  • History of treatment resistant depression (TRD) defined as 3 or more failed ADTs of adequate dose (per ATRQ) and duration (at least 8 weeks) for the current MDE
  • History of alcohol or substance use disorder according to criteria 6 months before the Screening Visit
  • Evidence of significant risk for suicidal behavior during participation in the study in the Investigator's opinion
  • Lifetime diagnosis of any psychotic disorder including MDD with psychosis, MDD with mixed features, bipolar I/II disorder, bipolar depression, schizophrenia, posttraumatic stress disorder, autism spectrum disorder, or any personality disorder or intellectual disability that would affect the ability of the participant to enroll in the study
  • Diagnosis less then 12 months before screening of severe obsessive-compulsive disorder, acute stress disorder, panic disorder, eating disorders, or any other psychiatric condition that has been the primary focus of treatment, or diagnosis of generalized anxiety disorder less then 6 months before screening.
  • History of cardiovascular, respiratory, gastrointestinal, renal, hepatic, and hematologic disorders, or other medical disorders that could impose undue risk or compromise the study in the Investigator's opinion
  • abnormal result prior to Day 1 Visit per Investigator's judgment or abnormal renal function.
  • Requires treatment with a medication or other substance that is prohibited by the protocol.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
230 participants (estimated)

Study arms

  • Experimental
    SPN-821 2400 mg

    Three 800 mg oral tablets administered twice a week adjunctive to current antidepressant

    Drug: SPN-821 2400 mg

  • Placebo comparator
    Placebo

    Three oral tablets administered twice a week adjunctive to current antidepressant

    Drug: Placebo

Interventions

  • DrugSPN-821 2400 mg

    SPN-821 is a novel, orally bioavailable, selective, direct enhancer of mTORC1 cellular signaling

  • DrugPlacebo

    Matched placebo oral tablets

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Day 29 in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score.

    MADRS is a 10-item scale (Reported sadness, Apparent sadness, Inner tension, Reduced sleep, Reduced appetite, Concentration difficulties, Lassitude, Inability to feel, Pessimist thoughts, and Suicidal thoughts) where each item is scored from 0 to 6. The total score is the sum of the 10 items ranging from 0 to 60 where higher scores indicate more severe depression, and lower scores are better outcomes.

    Time frame: 4 weeks

Secondary outcomes

  1. Change From Baseline to Day 29 in the Clinical Global Impression - Severity of Illness Score (CGI-S).

    CGI-S is a single-item clinician rating of the clinician's assessment of the severity of symptoms in relation to the clinician's total experience with patients with that condition. The CGI-I is rated on a 7-point scale from 1 to 7, where 1 = "normal not at all ill" and 7 = "among the most extremely ill patients". Successful therapy is indicated by a lower overall score.

    Time frame: 4 weeks

07

Study locations

40 of 40 sites recruiting
  • University of Alabama
    Birmingham, Alabama 35233, United States
    Recruiting
  • IMA Clinical Research Phoenix
    Phoenix, Arizona 85012, United States
    Recruiting
  • Woodland Research Northwest (ERG)
    Rogers, Arkansas 72758, United States
    Recruiting
  • Inland Psychiatric Medical Group
    Chino, California 91710, United States
    Recruiting
  • Leading Edge Research (Eximia Network)
    Encino, California 91316, United States
    Recruiting
  • Cenexel Collaborative Neuroscience Network
    Garden Grove, California 92845, United States
    Recruiting
  • Synergy Research (ERG Network)
    Lemon Grove, California 91945, United States
    Recruiting
  • Catalina Research Institute (Elixia)
    Montclair, California 91763, United States
    Recruiting
  • ATP Clinical Research
    Orange, California 92866, United States
    Recruiting
  • NRC Research Institute
    Orange, California 92868, United States
    Recruiting
  • Lumos Clinical Research Center
    San Jose, California 95124, United States
    Recruiting
  • Inland Psychiatric Medical Group
    Temecula, California 92591, United States
    Recruiting
  • Mountain View Clinical Research
    Denver, Colorado 80209, United States
    Recruiting
  • CT Clinical Research
    Cromwell, Connecticut 06416, United States
    Recruiting
  • CNS Healthcare - Jacksonville
    Jacksonville, Florida 32256, United States
    Recruiting
  • Avantis Clinical Research
    Miami, Florida 33155, United States
    Recruiting
  • CNS Healthcare of Orlando
    Orlando, Florida 32801, United States
    Recruiting
  • Space Coast Neuropsychiatric Research Institute
    Palm Bay, Florida 32905, United States
    Recruiting
  • Cenexel Tampa
    Tampa, Florida 33613, United States
    Recruiting
  • Interventional Psychiatry of Tampa Bay
    Tampa, Florida 33629, United States
    Recruiting
  • Cenexel Atlanta (ACMR)
    Atlanta, Georgia 30331, United States
    Recruiting
  • Cenexel iResearch Atlanta
    Decatur, Georgia 30030, United States
    Recruiting
  • AMR Conventions Research
    Warrenville, Illinois 60555, United States
    Recruiting
  • Precise Clinical Research
    Flowood, Mississippi 39232, United States
    Recruiting
  • Psychiatric Care and Research Center
    O'Fallon, Missouri 63368, United States
    Recruiting
  • Midwest Research Group
    Saint Charles, Missouri 63304, United States
    Recruiting
  • Vector Clinical Trials
    Las Vegas, Nevada 89128, United States
    Recruiting
  • Cenexel Marlton (HRI)
    Marlton, New Jersey 08053, United States
    Recruiting
  • SPRI Clinical Trials
    Brooklyn, New York 11235, United States
    Recruiting
  • Manhattan Behavioral Medicine
    New York, New York 10036, United States
    Recruiting
  • New Hope Clinical Research
    Charlotte, North Carolina 28211, United States
    Recruiting
  • Paradigm Research Professionals
    Oklahoma City, Oklahoma 73116, United States
    Recruiting
  • Summit Headlands (Headlands Research)
    Portland, Oregon 97210, United States
    Recruiting
  • Houston Clinical Trials
    Bellaire, Texas 77401, United States
    Recruiting
  • Baylor College of Medicine
    Houston, Texas 77030, United States
    Recruiting
  • DM Clinical
    Houston, Texas 77081, United States
    Recruiting
  • Grayline Research Center
    Wichita Falls, Texas 76309, United States
    Recruiting
  • Alpine Research Organization
    Clinton, Utah 84015, United States
    Recruiting
  • Aura Wellness
    Salt Lake City, Utah 84105, United States
    Recruiting
  • Core Clinical Research
    Everett, Washington 98201, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.

Of 98 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's planned 11 months is below that.

Counting every sponsor, half of 197 studies reached it within 22 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2025
First posted
Nov 10, 2025
StartActual
Jan 19, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jan 31, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
40 sites added, 1 site removed
Show 40 added (40 United States)
  • University of Alabama · Birmingham, United States
  • IMA Clinical Research Phoenix · Phoenix, United States
  • Woodland Research Northwest (ERG) · Rogers, United States
  • Inland Psychiatric Medical Group · Chino, United States
  • Leading Edge Research (Eximia Network) · Encino, United States
  • Cenexel Collaborative Neuroscience Network · Garden Grove, United States
  • Synergy Research (ERG Network) · Lemon Grove, United States
  • Catalina Research Institute (Elixia) · Montclair, United States
  • ATP Clinical Research · Orange, United States
  • NRC Research Institute · Orange, United States
  • Lumos Clinical Research Center · San Jose, United States
  • Inland Psychiatric Medical Group · Temecula, United States
  • Mountain View Clinical Research · Denver, United States
  • CT Clinical Research · Cromwell, United States
  • CNS Healthcare - Jacksonville · Jacksonville, United States
  • Avantis Clinical Research · Miami, United States
  • CNS Healthcare of Orlando · Orlando, United States
  • Space Coast Neuropsychiatric Research Institute · Palm Bay, United States
  • Cenexel Tampa · Tampa, United States
  • Interventional Psychiatry of Tampa Bay · Tampa, United States
  • Cenexel Atlanta (ACMR) · Atlanta, United States
  • Cenexel iResearch Atlanta · Decatur, United States
  • AMR Conventions Research · Warrenville, United States
  • Precise Clinical Research · Flowood, United States
  • Psychiatric Care and Research Center · O'Fallon, United States
  • Midwest Research Group · Saint Charles, United States
  • Vector Clinical Trials · Las Vegas, United States
  • Cenexel Marlton (HRI) · Marlton, United States
  • SPRI Clinical Trials · Brooklyn, United States
  • Manhattan Behavioral Medicine · New York, United States
  • …and 10 more on the registry record
Show 1 removed
  • Collaborative Neuroscience Network · Garden Grove, United States
Oct 28, 2026
Contact
Study contact's phone or email changed: •••2521→•••2500; g•••@supernus.com→c•••@supernus.com. See the current contact
Nov 16, 2026
Show all 2 updates
  1. Nov 16, 2026
    Contact Study contact's phone or email changed: •••2521→•••2500; g•••@supernus.com→c•••@supernus.com. See the current contact
  2. Oct 28, 2026
    40 sites added, 1 site removed
    Show 40 added (40 United States)
    • University of Alabama · Birmingham, United States
    • IMA Clinical Research Phoenix · Phoenix, United States
    • Woodland Research Northwest (ERG) · Rogers, United States
    • Inland Psychiatric Medical Group · Chino, United States
    • Leading Edge Research (Eximia Network) · Encino, United States
    • Cenexel Collaborative Neuroscience Network · Garden Grove, United States
    • Synergy Research (ERG Network) · Lemon Grove, United States
    • Catalina Research Institute (Elixia) · Montclair, United States
    • ATP Clinical Research · Orange, United States
    • NRC Research Institute · Orange, United States
    • Lumos Clinical Research Center · San Jose, United States
    • Inland Psychiatric Medical Group · Temecula, United States
    • Mountain View Clinical Research · Denver, United States
    • CT Clinical Research · Cromwell, United States
    • CNS Healthcare - Jacksonville · Jacksonville, United States
    • Avantis Clinical Research · Miami, United States
    • CNS Healthcare of Orlando · Orlando, United States
    • Space Coast Neuropsychiatric Research Institute · Palm Bay, United States
    • Cenexel Tampa · Tampa, United States
    • Interventional Psychiatry of Tampa Bay · Tampa, United States
    • Cenexel Atlanta (ACMR) · Atlanta, United States
    • Cenexel iResearch Atlanta · Decatur, United States
    • AMR Conventions Research · Warrenville, United States
    • Precise Clinical Research · Flowood, United States
    • Psychiatric Care and Research Center · O'Fallon, United States
    • Midwest Research Group · Saint Charles, United States
    • Vector Clinical Trials · Las Vegas, United States
    • Cenexel Marlton (HRI) · Marlton, United States
    • SPRI Clinical Trials · Brooklyn, United States
    • Manhattan Behavioral Medicine · New York, United States
    • …and 10 more on the registry record
    Show 1 removed
    • Collaborative Neuroscience Network · Garden Grove, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07226661
Responsible party
Sponsor
First posted
Nov 10, 2025
Start date
Jan 19, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Gianpiera Ceresoli-Borroni, PhD
Contact
clinicaltrials@supernus.com
301-838-2500

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion